Data on two deceased individuals with COVID-19 and comorbidities such as hepatitis C, chronic kidney disease, diabetes mellitus type 2 and hypertension are discussed. Changes in laboratory signatures with impact on COVID-19 severity in both cases indicate the need for extensive monitoring of comorbid individuals to reduce morbidity and mortality.